|Mr. Ram Mukunda||Pres, CEO & Director||461k||N/A||1959|
|Ms. Claudia Grimaldi||VP & Principal Financial Officer||173k||N/A||1971|
|Mr. Rohit Goel||Mang. & Principal Accounting Officer||N/A||N/A||1994|
|Mr. Shajy Mathilakathu||Co-Principal Financial & Accounting Officer||N/A||N/A||1968|
|Dr. Jagadeesh Rao||Scientific Officer||N/A||N/A||1967|
India Globalization Capital, Inc. purchases and resells infrastructure commodities. The company operates through two segments, Infrastructure Business, and Plant and Cannabinoid Business. It buys and sells infrastructure commodities, such as steel, marble, and tiles; rents heavy construction equipment, such as bulldozers, excavators, rollers, and pavers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of elderly patients from dementia, including Alzheimer's disease; Serosapse for the treatment of certain indications of Parkinson's disease and central nervous system disorders; and Natrinol for the treatment of certain indications of neuropathic pain. In addition, it offers hemp crude extracts, hemp isolates, and hemp distillates. The company operates in the United States, India, and Hong Kong. India Globalization Capital, Inc. was founded in 2005 and is based in Potomac, Maryland.
India Globalization Capital, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.